Study Finds Z-CAN Program, Supported by Medicines360, Increased Use of LARCs by Women in Puerto Rico During Zika Outbreak

Access to Full Range of Contraception, Plus Patient-Centered Counseling, Successful Formula for Woman-led Prevention of Unintended Pregnancy

SAN FRANCISCO – Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today highlighted a new report published in The Lancet Public Health. The report examined the effectiveness of the CDC Foundation’s (CDCF) Zika Contraception Access Network (Z-CAN) in Puerto Rico as a response to the Zika epidemic. Medicines360 was a proud supporter of the initiative to help providers educate women on the full range of contraceptive options and make those options available same-day at no cost.

Prevention of unintended pregnancy is a primary strategy to reduce adverse Zika-related pregnancy and birth outcomes. This led the CDCF, with technical assistance from Centers for Disease Control and Prevention (CDC) and a diverse group of stakeholders and organizations, including Medicines360, to establish Z-CAN. This network of 153 specially trained participating providers offered client-centered contraceptive counseling and a full range of reversible contraception options at no cost to women who wanted to avoid pregnancy during the 2016-17 Zika virus outbreak. The Lancet Public Health published a study authored by Eva Lathrop, MD, MPH, and colleagues examining the initial results on the impact of Z-CAN.

The study found that while 4 percent of women in the program (767) had used a long-acting reversible contraceptive (LARC) before Z-CAN, 68 percent (14,259) chose and received a LARC method at their initial visit with a provider in the Z-CAN network. Of the women participating in a patient satisfaction survey, 93 percent said they were very satisfied with the services received.

“When the full range of contraceptives is made readily available alongside patient-centered education and counseling, women and their families are better equipped to avoid the economic, societal and health burdens associated with unintended pregnancy. This has now been shown in the case of the Zika epidemic in Puerto Rico,” said Jessica Grossman, MD, Chief Executive Officer of Medicines360. “Through our support and that of other organizations via the CDC Foundation, women in Puerto Rico have gained increased control over their own health. We are committed to closing gaps in women’s access to medicines, and are delighted that the Z-CAN program has been shown to be an effective model for rapid implementation of reversible contraceptive services in an emergency setting.”

A pregnant woman, even one without symptoms, can pass Zika to her developing fetus; infection during pregnancy can cause serious birth defects. In 2016, the CDC estimated that 65 percent of pregnancies in Puerto Rico were unintended and approximately 138,000 women were at risk for unintended pregnancy. The CDC also noted that contraception access in Puerto Rico was limited by reduced availability of the full range of reversible methods, high out-of-pocket costs, a lack of patient education, and a shortage of providers trained in insertion, removal and management of LARCs. By supporting Z-CAN’s efforts, Medicines360 progressed its mission of expanding access to quality medicines for women around the globe.

About Medicines360

Medicines360, located in San Francisco, California, is a nonprofit global women’s health pharmaceutical company with a mission to expand access to quality medicines for all women regardless of their socioeconomic status, insurance coverage or geographic location. Medicines360 is committed to working with healthcare providers, advocacy groups and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit

About Medicines360

Located in San Francisco, California, Medicines360 is a global nonprofit pharmaceutical organization with a mission to accelerate the timeline from health innovation to access for all women. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.